deltatrials
Completed PHASE1 NCT00045370

Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

A Phase I Study of the Safety, Tolerability, and Antitumor Activity of Escalating Doses of Intravenous CCI-779 Given in Combination With Escalating Doses of Interferon-Alpha to Patients With Advanced Renal Cancer

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Kidney Cancer
Interventions recombinant interferon alfa temsirolimus
Updated 5 times since 2017 Last updated: Jun 4, 2013 Started: Apr 30, 2002 Primary completion: Nov 30, 2003 Completion: Nov 30, 2003

A PHASE1 clinical study on Kidney Cancer, this trial is completed. The trial is conducted by Memorial Sloan Kettering Cancer Center and has accumulated 5 data snapshots since 2002. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Apr 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Memorial Sloan Kettering Cancer Center
  • National Cancer Institute (NCI)
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New York, United States